EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival

José María Sayagués iD, Juan Carlos Montero iD, Andrea Jiménez-Pérez, Sofía Del Carmen, Marta Rodríguez iD, Rosario Vidal Tocino iD, Enrique Montero, Julia Sanz, Mar Abad

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von José María Sayagués und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and IBSAL, University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gerencia Regional de Salud de la Junta de Castilla y León, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sporadic colorectal cancer (sCRC) initially presents as metastatic tumors in 25–30% of patients. The 5-year overall survival (OS) in patients with metastatic sCRC is 50%, falling to 10% in patients presenting with synchronous metastatic disease (stage IV). In this study, we systematically analyzed the mutations of RAS, PIK3CA and BRAF genes in circulating tumor DNA (ctDNA) and tumoral tissue DNA (ttDNA) from 51 synchronous metastatic colorectal carcinoma (SMCC) patients by real-time PCR, and their relationship with the clinical, biological and histological features of disease at diagnosis. The highest frequency of mutations detected was in the KRAS gene, in tumor biopsies and plasma samples, followed by mutations of the PIK3CA, NRAS and BRAF genes. Overall, plasma systematically contained those genetic abnormalities observed in the tumor biopsy sample from the same subject, the largest discrepancies detected between the tumor biopsy and plasma from the same patient being for mutations in the KRAS and PIK3CA genes, with concordances of genotyping results between ttDNA and ctDNA at diagnosis of 75% and 84%, respectively. Of the 51 SMCC patients in the study, 25 (49%) showed mutations in at least 1 of the 4 genes analyzed in patient plasma. From the prognostic point of view, the presence and number of the most common mutations in the RAS, PIK3CA and BRAF genes in plasma from SMCC patients are independent prognostic factors for OS. Determination of the mutational status of ctDNA in SMCC could be a key tool for the clinical management of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)MutationClass I Phosphatidylinositol 3-KinasesBiomarkers, TumorDNA Mutational Analysis

Stichwörter der Autor:innen

BRAFKRASNRASPIK3CAanti-EGFRanti-VEGFliquid biopsysynchronous metastatic colorectal cancer

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Class I Phosphatidylinositol 3-KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and IBSAL, University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
  • Biomedical Research Networking Centers-Oncology (CIBERONC), 28029 Madrid, Spain.
  • Department of Pathology, University Hospital of Marqués de Valdecilla, 39008 Santander, Spain.
  • Department of Oncology and IBSAL, University Hospital of Salamanca, 37007 Salamanca, Spain.
  • Department of Pathology, University Hospital of Zamora, 49071 Zamora, Spain.
  • Department of Pathology, Puerto Real University Hospital, 11510 Cadiz, Spain.

ORCID-Profile: José María Sayagués, Juan Carlos Montero, Marta Rodríguez, Rosario Vidal Tocino

Förderung

  • Gerencia Regional de Salud de la Junta de Castilla y León
  • Gerencia Regional de Salud de Castilla y León, Valladolid, Spain

Zitieren

APA

Sayagués, J. M., Montero, J. C., Jiménez-Pérez, A., Del Carmen, S., Rodríguez, M., Vidal Tocino, R., Montero, E., Sanz, J., & Abad, M. (2023). Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098438

Vancouver

Sayagués JM, Montero JC, Jiménez-Pérez A, Del Carmen S, Rodríguez M, Vidal Tocino R, et al. Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098438

BibTeX
@article{Sayagus2023,
  author = {Sayagués, José María and Montero, Juan Carlos and Jiménez-Pérez, Andrea and Del Carmen, Sofía and Rodríguez, Marta and Vidal Tocino, Rosario and Montero, Enrique and Sanz, Julia and Abad, Mar},
  title = {Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098438}
}
Kostenlos starten →